OREGON HEALTH AUTHORITY

OSU Oregon State University College of Pharmacy
Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | Fax 503-947-1119

Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, December 5th, 2024
1:05 PM - 4:45 PM
Via Zoom webinar

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee, and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Stacy Ramirez, PharmD; Bridget Bradley, PharmD; Douglas Carr, MD; Russ Huffman, PMHNP; Cat Livingston, MD; Eddie Saito, PharmD; Jeanne Savage, MD; Samara Stevens, ND

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Megan Herink, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Brandon Wells; Dee Weston, JD; Jennifer Bowen; Kyle Hamilton; Michael Yu

Audience: Irene Luy*, Eli LIlly; Nirmal Ghuman* J&J; Aaron Huwe*, Merck; Andy Kim*, United Therapeutics; Djalal Nait Hammoud, Medunik; Abigail Hata*, Amgen; Chi Kohlhoff, Madrigal Pharmaceuticals; Sara Stolfus, Artia Solutions; Leanne Yantis; James Day, Texas Pharmaceuticals Initiative; Mike Corrigan, Recordati Rare Diseases; Peter Barrio; Chris Ferrin, IHN; Corinna Wong, PacificSource; Raya Nematian, Advanced Health; Lynda Finch, Biogen; Melissa Bailey Hall, Lilly USA; Lori McDermott, Viking HCS; Divine Marcelo, Amgen; Patrick Boland, BMS; Darlene Halverson; Craig Plauschinat, Eisai; Ben Szeto; Mark Kantor, AllCare Health; Paul Ford; Ron Abraham, Recordati Rare Diseases; Melissa Snider, Gilead; Lisa Pulver;

(*) Provided verbal testimony

I. CALL TO ORDER

A. Roll Call & Introductions
- Called to order at approx. 1:05 p.m., introductions by Committee and staff

B. Conflict of Interest Declaration – no new conflicts of interest were declared

C. Approval of Agenda and October 2024 Minutes presented by Roger Citron, RPh
ACTION: Motion to approve, 2nd, all in favor

D. Department Update provided by Andrew Gibler, PharmD

E. Early and Periodic Screening, Diagnostic & Treatment (EPSDT) Program Policy Update presented by Dee Weston, JD

OREGON HEALTH AUTHORITY

OSU Oregon State University College of Pharmacy

Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | Fax 503-947-1119

II. CONSENT AGENDA TOPICS

A. Quarterly Utilization Report

B. Attention Deficit Hyperactivity Disorder (ADHD) Drugs Literature Scan
Recommendations:
- No changes to the PDL are recommended based on review of the evidence
- Maintain Onyda™ XR (clonidine ER oral suspension) as voluntary non-preferred
- Evaluate costs in executive session

C. Oncology Prior Authorization (PA) Updates
Recommendation:
- Add: Tecentriq Hybreza™ (atezolizumab and hyaluronidase-tqjs); Itovebi™ (inavolisib); and Vyloy® (zolbetuximab-clzb) to Table 1 in the Oncology Agents PA criteria
ACTION: Motion to approve, 2nd, all in favor

III. DUR ACTIVITIES

A. ProDUR Report: Lan Starkweather, PharmD

B. RetroDUR Report: Dave Engen, PharmD

C. Oregon State Drug Review: Kathy Sentena, PharmD
1. Medication Holidays
2. Safety Risks Associated with Long-Term Use of Proton Pump Inhibitors
3. Critical Access Pharmacy Programs

IV. NEW BUSINESS

A. Orphan Drugs and Biologics for Rare Diseases PA Update: Sara Fletcher , PharmD
Recommendation:
- Move Uplinza® (inebilizumab-cdon), Ultomiris® (ravulizumab-cwvz), Enspryng® (satralizumab-mwge), Soliris® (eculizumab), Bkemv™ (eculizumab-aeeb), Epysqli® (eculizumab-aagh), Empaveli® (pegcetacoplan), and PiaSky® (crovalimab-akkz) to the orphan drug class; remove their PDL designation; retire their drug specific PA criteria; and apply the Orphan Drugs policy
- Update Table 1 in the Orphan Drugs PA criteria to support medically appropriate use of Aqneursa™ (levacetylleucine), and Miplyffa™ (arimoclomol citrate) based on FDA-approved labeling
ACTION: Motion to approve, 2nd, all in favor

B. Targeted Therapy for Alzheimer's Disease Class Update and New Drug Evaluation (NDE): Dave Engen, PharmD
Recommendations:
- Designate Kisunla™ (donanemab) as non-preferred on the PDL
- Implement PA for donanemab
- Update existing PA criteria as proposed
Public Comment: Irene Luy, Eli Lilly
ACTION: Motion to approve, 2nd, all in favor

OREGON HEALTH AUTHORITY

OSU Oregon State University College of Pharmacy
Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | Fax 503-947-1119

C. **Pulmonary Arterial Hypertension (PAH) Drugs Class Update, NDE, and Drug Use Evaluation (DUE)**: Sarah Servid, PharmD

Recommendations:

- Implement PA criteria for Winrevair™ (sotatercept-csrk) to support use as add-on treatment in PAH
- No changes to the PDL are recommended based on review of the evidence
- Implement PA for preferred PDE-5 inhibitors to prevent coverage for treatment of erectile dysfunction in men. Auto-approve prescriptions for any of the following criteria:
    - o PAH;
    - o Prior claims for other PAH drug classes; OR
    - o Prescriptions written by a pulmonologist
- Evaluate costs in executive session

Public Comment: Nirmal Ghuman, J&J; Aaron Huwe, Merck; Andy Kim, United Therapeutics

ACTION: Motion to approve, 2nd, all in favor

D. **Chronic Obstructive Pulmonary Disease (COPD) Class Update and NDE:** Deanna Moretz, PharmD

Recommendations:

- No changes to the PDL are recommended based on review of the evidence
- Update roflumilast PA criteria
- Update PA criteria for dupilumab to include use in adults with inadequately controlled COPD on triple inhaler therapy
- Maintain Ohtuvayre™ (ensifentrine) as non-preferred on the PDL and implement proposed PA criteria to ensure patient is using guideline directed therapy prior to adding ensifentrine to therapeutic regimen

ACTION: Motion to approve, 2nd, all in favor

E. **Urea Cycle Disorders Class Review:** Sara Fletcher, PharmD

Recommendations:

- Add class to the PDL
- Implement autoPA to allow continuation of therapy for the non-preferred agents
- Evaluate costs in executive session

Public Comment: Djalal Nait Hammoud, Medunik; Abigail Hata, Amgen

ACTION: Motion to approve, 2nd, all in favor

F. **Bone Metabolism Drugs Class Update:** Deanna Moretz, PharmD

Recommendations:

- No changes to the PDL are recommended based on review of the evidence
- Revise Bone Metabolism Agents PA criteria to align with recently published guidelines and FDA safety alerts
- Evaluate costs in executive session

Public Comment: Shannon DiBartolo, Amgen

ACTION: Motion to approve, 2nd, all in favor

OREGON HEALTH AUTHORITY

OSU Oregon State University College of Pharmacy
Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | Fax 503-947-1119

G. Platelet Inhibitors Class Update: Kathy Sentena, PharmD

Recommendations:

- Make ticagrelor preferred on the PDL due to evidence of superior efficacy compared to other antiplatelets for some indications
- Retire Platelet Inhibitors PA criteria and default to general Non-Preferred Drugs PA criteria

ACTION: Motion to approve, 2nd, all in favor

V. EXECUTIVE SESSION

Members Present: Stacy Ramirez, PharmD; Bridget Bradley, PharmD; Douglas Carr, MD; Russ Huffman, PMHNP; Cat Livingston, MD; Eddie Saito, PharmD; Jeanne Savage, MD; Samara Stevens, ND

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Brandon Wells

VI. RECONVENE for PUBLIC RECOMMENDATIONS

A. ADHD Drugs Literature Scan

Recommendation: Make dextroamphetamine ER capsules, amphetamine tablets and methylphenidate ER tablets preferred

ACTION: Motion to approve, 2nd, all in favor

B. PAH Drugs

Recommendations: Make tadalafil tablets preferred

ACTION: Motion to approve, 2nd, all in favor

C. Urea Cycle Disorders Class

Recommendations: Make Pheburane preferred and accept SR; make Buphenyl and generics preferred; and make Ravicti and Olpruva non-preferred

ACTION: Motion to approve, 2nd, all in favor

D. Bone Metabolism Drugs

Recommendation: No PDL changes recommended

ACTION: Motion to approve, 2nd, all in favor

VII. ADJOURN